Please login to the form below

Not currently logged in
Email:
Password:

Syros appoints Moderna CEO to board

Stéphane Bancel also has experience at bioMérieux and Lilly
Syros Stephane Bancel

The founding CEO of Moderna Therapeutics, Stéphane Bancel, has joined the board of Syros Pharmaceuticals.

Syros, which focuses on controlling a person's genes to treat cancer and other diseases, will benefit from Bancel's work in RNA therapeutics at Moderna.

The company's CEO Nancy Simonian said: “Stéphane has established an exceptional track record of accomplishment in our industry. His successes in financing and building companies as well as in creating value are widely admired.”

Bancel joined Moderna in 2011, the year after its formation. Notable achievements as CEO include securing a licensing partnership with AstraZeneca potentially worth more than $400m.

Prior to serving as Moderna's CEO, Bancel spent four years as CEO of bioMérieux.

He also spent six years at Lilly, including a spell as country manager for Belgium.

Commenting on his appointment to the board of Syros, he said: “Syros' leadership in understanding gene control opens entirely new avenues to treat cancer and other serious diseases.

“The company's revolutionary approach creates significant opportunity to impact health and create value.”

27th November 2013

From: Research, Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics